

Product Datasheet

Sovilnesib

Catalog No. **BP-02008** · CAS **2410796-79-9** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Kinesin; Microtubule/Tubulin	Research area Cancer
---	--------------------------------

Molecular formula **C₂₆H₃₄F₂N₆O₄S**

Molecular weight **564.6480**

STRUCTURE



DESCRIPTION

Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC₅₀ value of 0.071 μM. Sovilnesib can be used for the research of cancer.

BIOLOGICAL ACTIVITY

In Vitro

Sovilnesib (AMG 650; 0-10 pM; 96 and 144 h; cancer cell lines) has anti-proliferative activity and inhibits tumor cell growth in a dose-dependent manner.

In Vivo

Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity.

SOLUBILITY

Soluble in DMSO 100 mg/mL

REFERENCES

- [1]. Payton MN, et, al. Kif18a inhibitors for treatment of neoplastic diseases. WO2021211549
- [2]. Tamayo NA, et, al. Kif18a inhibitors. WO2020132648.